Abstract:Nanomotors offer a new approach to treating inflammation‐related diseases. They actively target inflammation sites, control drug release, and improve treatment efficacy. Compared to traditional treatments and static nanomaterials, nanomotors have advantages in reducing side effects and costs. Inflammation is a physiological response of the body to harmful stimuli such as pathogens, damaged cells, or irritants, involving a series of cellular and molecular events. It is associated with various diseases including neurodegenerative disorders, cancer, and atherosclerosis, and is a leading cause of global mortality. Key inflammatory factors, such as Tumor Necrosis Factor‐alpha (TNF‐α), Interleukin‐1 (IL‐1), Interleukin‐6 (IL‐6), Monocyte Chemoattractant Protein‐1 (MCP‐1/CCL2), RANTES (CCL5), and prostaglandins, play central roles in inflammation and disease progression. Traditional treatments such as NSAIDs, steroids, biologic agents, and antioxidants have limitations. Recent advancements in nanomaterials present promising solutions for treating inflammation‐related diseases. Unlike nanomaterials that rely on passive targeting and face challenges in precise drug delivery, nanomotors, driven by chemical or optical stimuli, offer a more dynamic approach by actively navigating to inflammation sites, thereby enhancing drug delivery efficiency and therapeutic outcomes. Nanomotors allow for controlled drug release in response to specific environmental changes, such as pH and inflammatory factors, ensuring effective drug concentrations at disease sites. This active targeting capability enables the use of smaller drug doses, which reduces overall drug usage, costs, and potential side effects compared to traditional treatments. By improving precision and efficiency, nanomotors address the limitations of conventional therapies and represent a significant advancement in the treatment of inflammation‐related diseases. This review summarizes the latest research on nanomotor‐mediated treatment of inflammation‐related diseases and discusses the challenges and future directions for optimizing their clinical translation.

Nanotherapeutics: Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation (adv. Sci. 15/2019)

Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation

Recent Advances of Engineered Cell Membrane-Based Nanotherapeutics to Combat Inflammatory Diseases.

Neutrophil‐Based Delivery Systems for Nanotherapeutics

Nanotechnology-Mediated Immunomodulation Strategy for Inflammation Resolution

Nanomotors as Therapeutic Agents: Advancing Treatment Strategies for Inflammation‐Related Diseases

Anti‐Inflammatory Nanotherapies Based on Bioactive Cyclodextrin Materials

Biomimetic Nanoparticles for Inflammation Targeting

Development of nanoparticle‐based drug delivery system for inflammation treatment and diagnosis

Nanotechnology Reinforced Neutrophil-Based Therapeutic Strategies for Inflammatory Diseases Therapy

An Inflammation Self-Adaptive Nanocarrier for Highly Efficient Gene Therapy

Cell Membrane Biomimetic Nanoparticles for Inflammation and Cancer Targeting in Drug Delivery.

Genetically Engineered Cell Membrane–coated Nanoparticles for Targeted Delivery of Dexamethasone to Inflamed Lungs

Cell Membrane-Formed Nanovesicles for Disease-Targeted Delivery.

Update on Nanoparticle-Based Drug Delivery System for Anti-inflammatory Treatment

Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage

Neutrophils and Macrophages as Targets for Development of Nanotherapeutics in Inflammatory Diseases

Pathologically triggered in situ aggregation of nanoparticles for inflammation-targeting amplification and therapeutic potentiation

Recent advances in cell membrane camouflaged nanotherapeutics for the treatment of bacterial infection

Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases

Nanomedicine targeted anti-inflammatory therapy to deal with the 'crux' of rheumatoid arthritis